title: Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.
abstract: In prostate cancer, biomarkers may provide additional value above standard clinical and pathology parameters to predict outcome after specific therapy. The purpose of this study is to evaluate an 80 kDa fragment of the cell adhesion molecule e-cadherin as a serum biomarker. A broad spectrum of prostate cancer serum samples, representing different stages of prostate cancer disease, including benign prostatic hyperplasia (BPH), localised (Loc PCA) and metastatic prostate cancer (Met PCA), was examined for the cleaved product. There is a significant difference in the expression level of the 80 kDa fragment in the serum of healthy individuals vs patients with BPH and between BPH vs Loc PCA and Met PCA (P<0.001). Highest expression levels are observed in advanced metastatic disease. In the cohort of Loc PCA cases, there was no association between the 80 kDa serum concentration and clinical parameters. Interestingly, patients with an 80 kDa level of >7.9 microg l(-1) at the time of diagnosis have a 55-fold higher risk of biochemical failure after surgery compared to those with lower levels. This is the first report of the application of an 80 kDa fragment of e-cadherin as a serum biomarker in a broad spectrum of prostate cancer cases. At an optimised cutoff, high expression at the time of diagnosis is associated with a significantly increased risk of biochemical failure, potentially supporting its use for a tailored follow-up protocol for those patients.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Ulm, Prittwitzstrasse 43, Ulm 89075, Germany. rainer.kuefer@medizin.uni-ulm.de
authors.forename: R
authors.initials: R
authors.lastname: Kuefer
authors.forename: M D
authors.initials: MD
authors.lastname: Hofer
authors.forename: C S M
authors.initials: CS
authors.lastname: Zorn
authors.forename: O
authors.initials: O
authors.lastname: Engel
authors.forename: B G
authors.initials: BG
authors.lastname: Volkmer
authors.forename: M A
authors.initials: MA
authors.lastname: Juarez-Brito
authors.forename: M
authors.initials: M
authors.lastname: Eggel
authors.forename: J E
authors.initials: JE
authors.lastname: Gschwend
authors.forename: M A
authors.initials: MA
authors.lastname: Rubin
authors.forename: M L
authors.initials: ML
authors.lastname: Day
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D015820:Cadherins / Q000097:blood* / Q000737:chemistry*; D016022:Case-Control Studies; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments; D011379:Prognosis; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000235:genetics* / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D012016:Reference Values; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D010446:Peptide Fragments